EPZ011989

Catalog No.S7805 Batch:S780503

Print

Technical Data

Formula

C35H51N5O4·HCl

Molecular Weight 642.27 CAS No. 2095432-26-9
Solubility (25°C)* In vitro Ethanol 100 mg/mL (155.69 mM)
DMSO Insoluble
Water Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description EPZ011989 is a potent, selective, orally bioavailable EZH2 inhibitor with Ki of <3 nM.
Targets
EZH2 [1]
(Cell-free assay)
EZH1 [1]
(Cell-free assay)
<3 nM(Ki) 103 nM
In vitro EPZ011989 equipotently inhibits mutant and wild-type EZH2 with an inhibition constant (Ki) of <3 nM. EPZ011989 is also a specific EZH2 inhibitor with a >15-fold selectivity over EZH1 and >3000-fold selectivity relative to the Ki of 20 other histone methyltransferases (HMTs) tested. As evidenced by the human and rat liver microsomal turnover, EPZ011989 also exhibits metabolic stability. EPZ011989 reduces cellular H3K27 methylation in the Y641F, mutant-bearing human lymphoma cell line, WSU-DLCL2, with an IC50 below 100 nM[1]. EPZ011989 inhibits H3K27me3 in wild-type EZH2 AML cell lines (Kasumi-1, MOLM-13, and MV4-11) at a concentration of 0.625 μM after only four days of treatment. At these concentrations and this time point, no change in viability among these three cell lines is observed and only minimal proliferation inhibition in MV4-11 and MOLM-13 cells[2].
In vivo EPZ011989 demonstrates significant tumor growth inhibition in a mouse xenograft model of human B cell lymphoma. EPZ011989 is able to elicit robust methyl mark inhibition and antitumor activity[1].

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    WSU-DLCL2 cells

  • Concentrations

    0-10 μM

  • Incubation Time

    0-11 days

  • Method

    For assessment of cell proliferation and viability, exponentially growing cells are plated, in triplicate, in 96-well plates. Cells are incubated with increasing concentrations of EPZ011989. Viable cell number is determined every 3-4 days for up to 11 days using the Guava Viacount assay.

Animal Study:

[1]

  • Animal Models

    SCID mice

  • Dosages

    250 and 500 mg/kg

  • Administration

    p.o.

Selleck's EPZ011989 has been cited by 14 publications

Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid [ Cancers (Basel), 2024, 16(3):569.] PubMed: 38339323
Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia [ Cancers (Basel), 2024, 16(3)569] PubMed: 38339323
Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes [ Nat Cell Biol, 2023, 25(2):258-272] PubMed: 36635503
ANGPTL2-mediated epigenetic repression of MHC-I in tumor cells accelerates tumor immune evasion [ Mol Oncol, 2023, 10.1002/1878-0261.13490] PubMed: 37452654
Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responses [ Cancer Cell, 2022, 40(10):1190-1206.e9] PubMed: 36179686
Epigenomic priming of immune genes implicates oligodendroglia in multiple sclerosis susceptibility [ Neuron, 2022, S0896-6273(21)01089-8] PubMed: 35093191
Chemical-Empowered Human Adipose-Derived Stem Cells with Lower Immunogenicity and Enhanced Pro-angiogenic Ability Promote Fast Tissue Regeneration [ Stem Cells Transl Med, 2022, 11(5):552-565] PubMed: 35511745
Sevoflurane Offers Neuroprotection in a Cerebral Ischemia/Reperfusion Injury Rat Model Through the E2F1/EZH2/TIMP2 Regulatory Axis [ Mol Neurobiol, 2022, 10.1007/s12035-021-02602-8] PubMed: 35064540
Resistance to Pyrrolobenzodiazepine Dimers Is Associated with SLFN11 Downregulation and Can Be Reversed through Inhibition of ATR [ Mol Cancer Ther, 2021, 20(3):541-552] PubMed: 33653945
Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer [ Cancer Lett, 2020, S0304-3835(20)30632-7] PubMed: 33253790

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.